Different Clinical Relevance of Anti-Citrullinated Protein Antibodies in RA Patients

Overview

Journal Dokl Biochem Biophys

Specialties Biochemistry
Biophysics

Date 2023 Oct 13

PMID 37833605

Authors

A S Avdeeva

M V Cherkasova

E L Nasonov

Affiliations

Soon will be listed here.

Abstract

The objective of the study was to find a potential relationship between ACPAs and disease activity, bone destruction, and ACPA responses to various therapeutic regimens. The study included 232 patients with rheumatoid arthritis (RA); 90 patients had early RA, and 142 patients had an advanced stage of the disease. 77 (85.6%) patients with early RA were highly positive for anti-CCP, and 29 (70.7%) patients were highly positive for anti-MCV. A positive correlation was found between anti-MCV and DAS28 (r = 0.4; p = 0.04). As for advanced RA, 78 (80.4%) patients were high-positive for anti-CCP, and 70 (79.5%) were high-positive for anti-MCV. There was a positive correlation between anti-MCV concentration and SDAI (r = 0.4; p = 0.02), as well as CDAI (r = 0.4; p = 0.02). No significant correlations were found between the anti-CCP levels and activity indices, anti-CCP and acute-phase parameters in both early and advanced RA groups. Higher total Sharp scores (96.5 (65.0-122.0)) were found in pts highl-positive for anti-MCV (n = 79), compared to low-positive/negative (n = 27) patients (57.0 (31.0-88.0); p < 0.05). Anti-MCV levels dropped significantly in pts on rituximab and tocilizumab therapy at weeks 12 and 24 after initiation of treatment, while high anti-CCP concentration persisted throughout the treatment. Anti-MCV levels correlated with inflammatory activity and development of bone destruction and decreased in pts on treatment. Anti-CCP was less responsive and showed minor changes during treatment; therefore, its thorough monitoring was not feasible.

References

Mansour H, Metwaly K, Hassan I, Elshamy H, Elbeblawy M . Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clin Med Insights Arthritis Musculoskelet Disord. 2010; 3:33-42. PMC: 2989636. DOI: 10.4137/cmamd.s4827. View

Mathsson L, Mullazehi M, Wick M, Sjoberg O, van Vollenhoven R, Klareskog L . Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008; 58(1):36-45. DOI: 10.1002/art.23188. View

Krishnamurthy A, Joshua V, Hensvold A, Jin T, Sun M, Vivar N . Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2015; 75(4):721-9. PMC: 4819614. DOI: 10.1136/annrheumdis-2015-208093. View

Mastrangelo A, Colasanti T, Barbati C, Pecani A, Sabatinelli D, Pendolino M . The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis. J Immunol Res. 2015; 2015:712490. PMC: 4451265. DOI: 10.1155/2015/712490. View

Humphreys J, van Nies J, Chipping J, Marshall T, van der Helm-van Mil A, Symmons D . Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res Ther. 2014; 16(6):483. PMC: 4272533. DOI: 10.1186/s13075-014-0483-3. View

Roland P, Grootenboer Mignot S, Bruns A, Hurtado M, Palazzo E, Hayem G . Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther. 2008; 10(6):R142. PMC: 2656247. DOI: 10.1186/ar2570. View

Klareskog L, Catrina A, Paget S . Rheumatoid arthritis. Lancet. 2009; 373(9664):659-72. DOI: 10.1016/S0140-6736(09)60008-8. View

Aletaha D, Bluml S . Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016; 2(1):e000009. PMC: 4879342. DOI: 10.1136/rmdopen-2014-000009. View

Kerkman P, Fabre E, van der Voort E, Zaldumbide A, Rombouts Y, Rispens T . Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis. 2015; 75(6):1170-6. DOI: 10.1136/annrheumdis-2014-207182. View

10.

Harre U, Lang S, Pfeifle R, Rombouts Y, Fruhbeisser S, Amara K . Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun. 2015; 6:6651. PMC: 4389255. DOI: 10.1038/ncomms7651. View

11.

Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D . Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 66(6):818-20. PMC: 1954671. DOI: 10.1136/ard.2006.062505. View

12.

Cambridge G, Stohl W, Leandro M, Migone T, Hilbert D, Edwards J . Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006; 54(3):723-32. DOI: 10.1002/art.21650. View

13.

Zhang Z, Cao D, Zhang X, Ji R, Gao Y . Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain. 2013; 154(10):2185-2197. PMC: 3899784. DOI: 10.1016/j.pain.2013.07.002. View

14.

Tsiakalos A, Avgoustidis N, Moutsopoulos H . Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics. 2009; 2(4):911-6. PMC: 2727907. DOI: 10.2147/btt.s3939. View

15.

Syversen S, Goll G, van der Heijde D, Landewe R, Lie B, Odegard S . Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis. 2009; 69(2):345-51. DOI: 10.1136/ard.2009.113092. View

16.

Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E . Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012; 122(5):1791-802. PMC: 3336988. DOI: 10.1172/JCI60975. View

17.

Kuller L, Mackey R, Walitt B, Deane K, Holers V, Robinson W . Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis. Arthritis Rheumatol. 2014; 66(3):497-507. PMC: 5638120. DOI: 10.1002/art.38268. View

18.

Sakkas L, Bogdanos D, Katsiari C, Platsoucas C . Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. Autoimmun Rev. 2014; 13(11):1114-20. DOI: 10.1016/j.autrev.2014.08.012. View

19.

Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky D, Naredo E . Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016; 75(8):1428-37. DOI: 10.1136/annrheumdis-2016-209201. View

20.

Vossenaar E, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T . Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004; 6(2):R142-50. PMC: 400433. DOI: 10.1186/ar1149. View